Pub Date : 2023-12-31DOI: 10.23937/2643-4563/1710053
Sharma Aditya, Meena Ram Niwas, K. Anantha
Liver metastasis can be defined as the seeding of a malignant tumour from other organs affected by cancer. About half of the patients with colorectal cancer develop liver metastases during the progressive course of the disease. Surgery is the only curative treatment for patients with metastatic liver disease, and the five-year survival rate after resection of all detectable liver metastases can be as high as 40%. Unfortunately, only 25% of patients with liver metastases are candidates for liver resection. Regional treatments such as radiofrequency ablation and cryotherapy may be offered to patients with isolated, unresectable metastases but no evidence of extrahepatic disease. Chemotherapy and chemoembolization are often used in patients with liver metastases, but patients with extrahepatic disease are not suitable candidates for regional ablation. For patients with metastatic colorectal cancer beyond the liver, systemic chemotherapy is a better treatment option. Immunotherapy, when used with chemotherapeutic agents, has an additive therapeutic effect. More than half of the patients die of metastatic liver disease. Surgical resection of distant metastases can lead to prolonged survival and cure in a selected group of patients. This article reviews the current concepts along with recent advances and future perspectives in the management of patients with liver metastasis.
{"title":"Liver Metastasis: Current Concepts in Management and Future Perspectives","authors":"Sharma Aditya, Meena Ram Niwas, K. Anantha","doi":"10.23937/2643-4563/1710053","DOIUrl":"https://doi.org/10.23937/2643-4563/1710053","url":null,"abstract":"Liver metastasis can be defined as the seeding of a malignant tumour from other organs affected by cancer. About half of the patients with colorectal cancer develop liver metastases during the progressive course of the disease. Surgery is the only curative treatment for patients with metastatic liver disease, and the five-year survival rate after resection of all detectable liver metastases can be as high as 40%. Unfortunately, only 25% of patients with liver metastases are candidates for liver resection. Regional treatments such as radiofrequency ablation and cryotherapy may be offered to patients with isolated, unresectable metastases but no evidence of extrahepatic disease. Chemotherapy and chemoembolization are often used in patients with liver metastases, but patients with extrahepatic disease are not suitable candidates for regional ablation. For patients with metastatic colorectal cancer beyond the liver, systemic chemotherapy is a better treatment option. Immunotherapy, when used with chemotherapeutic agents, has an additive therapeutic effect. More than half of the patients die of metastatic liver disease. Surgical resection of distant metastases can lead to prolonged survival and cure in a selected group of patients. This article reviews the current concepts along with recent advances and future perspectives in the management of patients with liver metastasis.","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" 1131","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139136293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2643-4563/1710052
Portela Caio Fernando Teixeira, Mourão Arnaldo Prata
{"title":"Dose Variation Profiles of Small Fields with a 10 MV Photon Beam","authors":"Portela Caio Fernando Teixeira, Mourão Arnaldo Prata","doi":"10.23937/2643-4563/1710052","DOIUrl":"https://doi.org/10.23937/2643-4563/1710052","url":null,"abstract":"","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41954956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Symptomatic gastrointestinal metastases from lung cancer were considered quite rare given their low incidence, especially the duodenal location. In this article, we report a clinical case of a patient followed for a pulmonary adenocarcinoma revealed by a duodenal metastasis. The patient was a 63-year-old female. She was admitted to the oncology department of the Ibn Rochd University Hospital for a low digestive hemorrhage ‘’Melena’’ complicated by acute anemia. Duodenal metastasis from a primary adenocarcinoma of the lung was diagnosed following histopathological examination supplemented by immunohistochemical analysis of biopsies of the duodenal mass taken under gastrointestinal fibroscopy. Post-mortem studies have confirmed that large cell lung carcinoma is significantly associated with gastrointestinal metastases with an incidence ranging from 30% to 75.9%. For this reason, physicians should consider secondary gastrointestinal locations if patients with lung cancer exhibit digestive symptoms and not relate this symptom to side effects of chemotherapy.
{"title":"Duodenal Metastasis of a Pulmonary Adenocarcinoma: Report of a Case and Review of the Literature","authors":"Zaouit Maryam, Guebessii Nisrine Bennani, Oudad Fadwa, Khoaja Ayoub, Aaribi Imane, Hejjane Loubna, B. Nadia, Sahraoui Souha, Benider Abdellatif","doi":"10.23937/2643-4563/1710049","DOIUrl":"https://doi.org/10.23937/2643-4563/1710049","url":null,"abstract":"Symptomatic gastrointestinal metastases from lung cancer were considered quite rare given their low incidence, especially the duodenal location. In this article, we report a clinical case of a patient followed for a pulmonary adenocarcinoma revealed by a duodenal metastasis. The patient was a 63-year-old female. She was admitted to the oncology department of the Ibn Rochd University Hospital for a low digestive hemorrhage ‘’Melena’’ complicated by acute anemia. Duodenal metastasis from a primary adenocarcinoma of the lung was diagnosed following histopathological examination supplemented by immunohistochemical analysis of biopsies of the duodenal mass taken under gastrointestinal fibroscopy. Post-mortem studies have confirmed that large cell lung carcinoma is significantly associated with gastrointestinal metastases with an incidence ranging from 30% to 75.9%. For this reason, physicians should consider secondary gastrointestinal locations if patients with lung cancer exhibit digestive symptoms and not relate this symptom to side effects of chemotherapy.","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44584128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2643-4563/1710050
Ali Muhammad Adel, El Zohairy Mohamed Abd El Fattah, Hafez Nesreen Hassan, K. Amr
{"title":"Borderline Ovarian Tumors a Five-year Retrospective Clinicopathologic Study of 69 Cases in Egyptian NCI (2013-17)","authors":"Ali Muhammad Adel, El Zohairy Mohamed Abd El Fattah, Hafez Nesreen Hassan, K. Amr","doi":"10.23937/2643-4563/1710050","DOIUrl":"https://doi.org/10.23937/2643-4563/1710050","url":null,"abstract":"","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43169297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2643-4563/1710051
FG Mouamba, RG Buambo, L. Mozoma, B. Samba, GC Bizib, K. Mavoungou, B. Senga, JF Peko
{"title":"Two Cases of Primary Leiomyosarcoma of the Vagina: Histomorphologic Presentation with Review of the Literature","authors":"FG Mouamba, RG Buambo, L. Mozoma, B. Samba, GC Bizib, K. Mavoungou, B. Senga, JF Peko","doi":"10.23937/2643-4563/1710051","DOIUrl":"https://doi.org/10.23937/2643-4563/1710051","url":null,"abstract":"","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43036651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2643-4563/1710047
S. Panandtigri, N. Benchakroun, El Karim SYLLA Abdou, T. Chekrine, M. Bourhafour, Z. Bouchbika, H. Jouhadi, N. Tawfiq, S. Nani, S. Sahraoui
{"title":"Impact of the Covid-19 Pandemic on the Lung Cancer Management Process at the Mohamed VI Center for the Treatment of Cancer in Morocco","authors":"S. Panandtigri, N. Benchakroun, El Karim SYLLA Abdou, T. Chekrine, M. Bourhafour, Z. Bouchbika, H. Jouhadi, N. Tawfiq, S. Nani, S. Sahraoui","doi":"10.23937/2643-4563/1710047","DOIUrl":"https://doi.org/10.23937/2643-4563/1710047","url":null,"abstract":"","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47869764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2643-4563/1710046
B. Nidhal, Habouria Chaima, M. Hana, Maamar Malak, Bachouch Imen, Chermiti Fatma, Fenniche Soraya
Introduction: Interactions between cancer genesis, sleep quality and patient’s humor engage complex pathophysiological pathways. However, the outcome of various indicators of quality of life (Qol) after chemotherapy in non small cells lung cancer (NSCLC) and also their prognostic impact remain understudied. The objective of this study was to analyze the Qol, sleep quality and anxio-depressive disorder in advanced NSCLC patients put on chemotherapy. We aimed also to demonstrate the correlation between the Qol and overall survival (OS) of the cohort. Methods: In this monocentric prospective study, we included all patients with metastatic NSCLC, put on chemotherapy regimen from January to December 2018. We assessed the Qol, the sleep quality and disturbances of humor through dedicated questionnaires in Arabic Tunisian dialectal version. Concerning the outcome, the study mentioned the response to chemotherapy and the overall survival. The point date was on December 31st 2019. Results: Seventy one male patients were included. Their mean age was 62.17 years. Adenocarcinoma was the most frequent histologic type (58%) and then was squamous cell carcinoma (25%). When analyzing QLQ-C30, we found a significant correlation between the global Qol coefficient and the coefficient of performances, an inversely proportional correlation with the coefficient of symptoms. Analysis of PSQI score had shown a poor sleep quality in 55% of patients after chemotherapy. A depressive humor was detected in 21 patients (30%) and an anxious humor in 24 patients (34%). Twenty six patients (37%) had a tumor regression after 1st line of chemotherapy. Mean OS was 317 days (IC = 95% [292-377], margin of error of 20 days) with extremes from 1.6 months to 21 months. One year survival rate was 44%. Statistical analysis had shown a closely comparable OS in our patients, whatever was the chemotherapy regimen. OS was correlated to Performance Status, response to chemotherapy, good sleep quality and high levels of performance dimensions. Multivariate analysis found poor sleep quality and tumor progression after chemotherapy as independent predictive factors of mortality. Conclusions: Considering our results, we highlight the important decline of Qol in NSCLC patients, affecting several dimensions, whatever was the molecules of chemotherapy used. This decline would be predictive of a poor prognosis.
{"title":"Impact of Quality of Life on Prognosis of Metastatic Non-Small Cell Lung Cancer: Is It Correlated to the Chemotherapy Regimen Used?","authors":"B. Nidhal, Habouria Chaima, M. Hana, Maamar Malak, Bachouch Imen, Chermiti Fatma, Fenniche Soraya","doi":"10.23937/2643-4563/1710046","DOIUrl":"https://doi.org/10.23937/2643-4563/1710046","url":null,"abstract":"Introduction: Interactions between cancer genesis, sleep quality and patient’s humor engage complex pathophysiological pathways. However, the outcome of various indicators of quality of life (Qol) after chemotherapy in non small cells lung cancer (NSCLC) and also their prognostic impact remain understudied. The objective of this study was to analyze the Qol, sleep quality and anxio-depressive disorder in advanced NSCLC patients put on chemotherapy. We aimed also to demonstrate the correlation between the Qol and overall survival (OS) of the cohort. Methods: In this monocentric prospective study, we included all patients with metastatic NSCLC, put on chemotherapy regimen from January to December 2018. We assessed the Qol, the sleep quality and disturbances of humor through dedicated questionnaires in Arabic Tunisian dialectal version. Concerning the outcome, the study mentioned the response to chemotherapy and the overall survival. The point date was on December 31st 2019. Results: Seventy one male patients were included. Their mean age was 62.17 years. Adenocarcinoma was the most frequent histologic type (58%) and then was squamous cell carcinoma (25%). When analyzing QLQ-C30, we found a significant correlation between the global Qol coefficient and the coefficient of performances, an inversely proportional correlation with the coefficient of symptoms. Analysis of PSQI score had shown a poor sleep quality in 55% of patients after chemotherapy. A depressive humor was detected in 21 patients (30%) and an anxious humor in 24 patients (34%). Twenty six patients (37%) had a tumor regression after 1st line of chemotherapy. Mean OS was 317 days (IC = 95% [292-377], margin of error of 20 days) with extremes from 1.6 months to 21 months. One year survival rate was 44%. Statistical analysis had shown a closely comparable OS in our patients, whatever was the chemotherapy regimen. OS was correlated to Performance Status, response to chemotherapy, good sleep quality and high levels of performance dimensions. Multivariate analysis found poor sleep quality and tumor progression after chemotherapy as independent predictive factors of mortality. Conclusions: Considering our results, we highlight the important decline of Qol in NSCLC patients, affecting several dimensions, whatever was the molecules of chemotherapy used. This decline would be predictive of a poor prognosis.","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42501259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2643-4563/1710045
Al-Otaibi Hind Saad, A. Mohammed Hassan, Razak Ghaidaa Naser Abdul, Bakiratharajan David, Alanzi Talal Abdulla, Ahmed Tarek Essam Eldin
Leiomyosarcoma (LMS) are rare tumor associated with poor outcomes. Treatment of the condition is challenging due to limited cases in the literature. Here, we present the case of a 46-year-old male who presented with left lower limb deep vein thrombosis, with an ultrasound scan revealing right renal mass. MRI demonstrated a large, well-circumscribed lesion engulfing in the middle and lower right renal poles associated with an invasion of the related part of the IVC, right renal vein and mid-length of the left renal vein. The patient underwent right radical nephrectomy and IVC thrombectomy. Subsequent pathology was consistent with an LMS of the inferior vena cava. We document this case and discuss implications.
{"title":"Leiomyosarcoma of the Inferior Vena Cava Presenting as a Renal Mass: A Case Report","authors":"Al-Otaibi Hind Saad, A. Mohammed Hassan, Razak Ghaidaa Naser Abdul, Bakiratharajan David, Alanzi Talal Abdulla, Ahmed Tarek Essam Eldin","doi":"10.23937/2643-4563/1710045","DOIUrl":"https://doi.org/10.23937/2643-4563/1710045","url":null,"abstract":"Leiomyosarcoma (LMS) are rare tumor associated with poor outcomes. Treatment of the condition is challenging due to limited cases in the literature. Here, we present the case of a 46-year-old male who presented with left lower limb deep vein thrombosis, with an ultrasound scan revealing right renal mass. MRI demonstrated a large, well-circumscribed lesion engulfing in the middle and lower right renal poles associated with an invasion of the related part of the IVC, right renal vein and mid-length of the left renal vein. The patient underwent right radical nephrectomy and IVC thrombectomy. Subsequent pathology was consistent with an LMS of the inferior vena cava. We document this case and discuss implications.","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45186267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2643-4563/1710044
Mehta Ritu, Y. Rashmi
Aim: To study the prevalence of Cyclin D1 expression and its correlation with other clinicopathological parameters like age, tumor size, lymph node status, MBR grade, and expression of other immunohistochemical markers like ER, PR, Her 2 - neu, and Ki67. Material and Methods: Thirty cases diagnosed were included in the study. All the cases were subjected to routine histopathology along with IHC for ER PR, Her2-neu, Ki67, and Cyclin D1. Results: CylinD1 positivity was found in 70% of cases. Our study presented the following distribution of cases Luminal A, N = 6(20%), Luminal B, N = 5(16.7%), Triple-negative, N = 10(33.3%), Normal Like = 7(23.3%), Her2/neu enriched = 2(6.7%). N = 4(40%) of triple-negative molecular subtype were positive for the cyclin D1. Cyclin D1 positivity showed a strong correlation with ER, PR, Her2-neu, and Ki67 status. However, no other significant correlation was found with other factors. Conclusion: This study shows a positive correlation of CyclinD1 with many other prognostic markers like molecular subtype, ER, PR, Her2/neu, and Ki67. With the advent of CD4/6 inhibitors and their potential therapeutic effects in breast carcinoma, Cyclin D1 becomes a potential prognostic IHC marker and can aid in patient management in cases of breast carcinoma. Its association with other established markers and clinicopathological parameters needs to be researched thoroughly.
{"title":"Carcinoma Breast: Correlation of Immunohistohemical Expression of Cyclin D1 and Its Correlation with Clinicopathological Parameters in Indian Patients at Tertiary Care Hospital","authors":"Mehta Ritu, Y. Rashmi","doi":"10.23937/2643-4563/1710044","DOIUrl":"https://doi.org/10.23937/2643-4563/1710044","url":null,"abstract":"Aim: To study the prevalence of Cyclin D1 expression and its correlation with other clinicopathological parameters like age, tumor size, lymph node status, MBR grade, and expression of other immunohistochemical markers like ER, PR, Her 2 - neu, and Ki67. Material and Methods: Thirty cases diagnosed were included in the study. All the cases were subjected to routine histopathology along with IHC for ER PR, Her2-neu, Ki67, and Cyclin D1. Results: CylinD1 positivity was found in 70% of cases. Our study presented the following distribution of cases Luminal A, N = 6(20%), Luminal B, N = 5(16.7%), Triple-negative, N = 10(33.3%), Normal Like = 7(23.3%), Her2/neu enriched = 2(6.7%). N = 4(40%) of triple-negative molecular subtype were positive for the cyclin D1. Cyclin D1 positivity showed a strong correlation with ER, PR, Her2-neu, and Ki67 status. However, no other significant correlation was found with other factors. Conclusion: This study shows a positive correlation of CyclinD1 with many other prognostic markers like molecular subtype, ER, PR, Her2/neu, and Ki67. With the advent of CD4/6 inhibitors and their potential therapeutic effects in breast carcinoma, Cyclin D1 becomes a potential prognostic IHC marker and can aid in patient management in cases of breast carcinoma. Its association with other established markers and clinicopathological parameters needs to be researched thoroughly.","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43825507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：